NCT00672620View on ClinicalTrials.gov

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

611

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions

Major Depressive Disorder

Interventions

DRUG

Vortioxetine

Encapsulated vortioxetine immediate-release tablets

DRUG

Duloxetine

Duloxetine capsules

DRUG

Placebo

Placebo-matching capsules

Trial Locations (38)

Unknown

Beverly Hills

Irvine

Santa Ana

Torrance

Upland

Bradenton

Coral Springs

Fort Walton Beach

Gainesville

Jacksonville

Maitland

Orlando

South Miami

West Palm Beach

Atlanta

Smyrna

Chicago

Libertyville

Oak Brook

Prairie Village

Owensboro

Baltimore

Pittsfield

Worcester

Flowood

New York

Olean

Beachwood

Toledo

Oklahoma City

Allenport

Lancaster

Memphis

Austin

San Antonio

Salt Lake City

Seattle

Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Takeda

INDUSTRY

NCT00672620 - Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter